Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Coulter Partners places Dr. David Rosenbaum as Chief Development Officer of Syntis Bio

BOSTON, MA and LONDON, UK – March 11, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Syntis Bio, Inc. and is pleased to announce the placement of David Rosenbaum, Ph.D. as Chief Development Officer (CDO). 

Bionow BioIgnite Conference 2026

BioIgnite: Sparking Growth Through Collaboration

Bionow's BioIgnite conference is back for 2026! Bringing together industry and academia to explore emerging innovation, sector initiatives and funding opportunities across life sciences, the bespoke agenda creates a focused environment for insight, discussion and connection.

Why Attend?

The 2026 UCL Business Ltd Impact Report is Published and Available to Read Below

For over 30 years, UCLB has built a sustained engine of commercial success, turning exceptional UCL research into ventures and licensing deals across every discipline.

The UCL 2026 Impact Report demonstrates how this work is having real-world impact, from changing patients’ lives with new personalised treatments for leukaemia, to making businesses more efficient with the use of AI tools, to empowering communities to have their voices heard with data and maps.

Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment

PHILADELPHIA, PA – February 26, 2026 – Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.

Senior Bioinformatician

We are seeking a talented and creative Senior Bioinformatician with a passion for using computational advances to prioritise and advance high-potential therapeutic antibodies and targets from Alchemab’s discovery platform through to the clinic.

Reporting into the Principal Bioinformatician, the Senior Bioinformatician will take a lead role in shaping and executing Alchemab’s computational target evaluation strategy by:

Subscribe to